Health & Environmental Research Online (HERO)


Print Feedback Export to File
1579292 
Journal Article 
Arsenic upregulates the expression of angiotensin II Type I receptor in mouse aortic endothelial cells 
Hossain, E; Ota, A; Takahashi, M; Karnan, S; Damdindorj, L; Konishi, Y; Konishi, H; Hosokawa, Y 
2013 
Toxicology Letters
ISSN: 0378-4274
EISSN: 1879-3169 
220 
70-75 
English 
Although chronic arsenic exposure is a well-known risk for cardiovascular disease and has a strong correlation with hypertension, the molecular pathogenesis underlying arsenic exposure-induced hypertension remains poorly understood. To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following sodium arsenite (SA) treatment. Flow cytometry analysis revealed that SA increases the generation of reactive oxygen species (ROS) in a dose-dependent manner. In addition, western blot analysis revealed that SA enhances the phosphorylations of c-Jun N-terminal kinases (JNK) and activated protein 1 (AP-1). These phosphorylations were inhibited by N-acetylcysteine (NAC), an anti-oxidant. Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific JNK inhibitor, SP6001325, strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway. Taken together, our results indicate that arsenic indeed upregulates the AT1R expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension. 
Arsenic exposure; Cardiovascular disease; Hypertension; Reactive oxygen species (ROS); Renin angiotensin system; Molecular biology 
IRIS
• Arsenic Hazard ID
          PubMed
          Considered New
          PubMed
          WOS
          Considered New
          ToxNet
          Considered New
          ToxNet
          Excluded
               Toxnet Duplicates
          ToxNet
          Excluded
               Toxnet Duplicates
          ToxNet
          Excluded
               Toxnet Duplicates
          ToxNet
          Excluded
               Toxnet Duplicates
          ToxNet
          Excluded
               Toxnet Duplicates
     2. Lit Search Updates through Oct 2015
          PubMed
          WOS
          ToxNet
          Considered
     7. Other Studies through Oct 2015
          MOA
• Arsenic (Inorganic)
     1. Literature
          Lit search updates through Oct 2015
     3. Hazard ID Screening
          Other potentially supporting studies
     4. Adverse Outcome Pathways/Networks Screening
          Relevant
• Arsenic MOA
     4. Adverse Outcome Pathways
          Vascular mechanisms
     1. MOA Literature Screening
          Health Effect Screening
• Arsenic Susceptibility
     Life Stages Citation Mapping
          20%-25%